Concord Medical Services Stock EBITDA

CCM Stock

USD 7.73 0.27 3.37%

Concord Medical Services fundamentals help investors to digest information that contributes to Concord Medical's financial success or failures. It also enables traders to predict the movement of Concord Stock. The fundamental analysis module provides a way to measure Concord Medical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Concord Medical stock.

		Last Reported	Projected for Next Year
	EBITDA	-313.7 M	-298.1 M

As of the 25th of October 2024, EBITDA is likely to grow to about (298.1 M).

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Concord Medical Services Company EBITDA Analysis

Concord Medical's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Concord Medical EBITDA

(313.75 M)

Most of Concord Medical's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Concord Medical Services is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Concord EBITDA Driver Correlations

Understanding the fundamental principles of building solid financial models for Concord Medical is extremely important. It helps to project a fair market value of Concord Stock properly, considering its historical fundamentals such as EBITDA. Since Concord Medical's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Concord Medical's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Concord Medical's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Long Term Debt	Good Will	Total Liab	Intangible Assets	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Current Assets	Short Term Debt	Short Term Investments	Treasury Stock	Net Tangible Assets	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Long Term Debt Total	Capital Surpluse	Cash And Equivalents	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		-0.57	0.78	0.64	0.83	0.82	0.72	0.75	0.73	0.79	-0.73	0.54	0.26	-0.13	0.31	-0.33	-0.63	-0.77	0.3	0.33	-0.32	0.74	0.67	0.1	-0.77	-0.35	-0.17
Total Stockholder Equity	-0.57		-0.92	-0.74	-0.82	-0.64	-0.04	-0.94	-0.73	-0.86	0.95	-0.47	0.35	0.6	-0.21	0.78	0.65	0.91	-0.27	-0.39	0.16	-0.94	-0.68	-0.03	0.91	0.69	0.57
Long Term Debt	0.78	-0.92		0.76	0.9	0.72	0.32	0.98	0.83	0.94	-0.96	0.52	-0.11	-0.52	0.22	-0.66	-0.72	-0.94	0.41	0.33	-0.32	0.98	0.74	0.0	-0.9	-0.6	-0.46
Good Will	0.64	-0.74	0.76		0.72	0.49	0.32	0.82	0.65	0.81	-0.87	0.84	-0.25	-0.49	0.34	-0.4	-0.28	-0.76	0.11	0.28	0.16	0.79	0.31	-0.02	-0.81	-0.75	-0.63
Total Liab	0.83	-0.82	0.9	0.72		0.74	0.53	0.93	0.65	0.96	-0.9	0.58	-0.06	-0.22	0.58	-0.6	-0.77	-0.88	0.39	0.42	-0.29	0.92	0.81	0.03	-0.85	-0.68	-0.6
Intangible Assets	0.82	-0.64	0.72	0.49	0.74		0.42	0.69	0.63	0.64	-0.67	0.28	0.19	-0.18	0.15	-0.54	-0.81	-0.72	0.31	0.44	-0.35	0.68	0.81	0.18	-0.78	-0.21	-0.1
Common Stock	0.72	-0.04	0.32	0.32	0.53	0.42		0.35	0.19	0.45	-0.29	0.25	0.32	0.27	0.48	0.2	-0.38	-0.35	0.19	0.11	-0.27	0.33	0.42	0.02	-0.31	-0.22	-0.17
Property Plant Equipment	0.75	-0.94	0.98	0.82	0.93	0.69	0.35		0.74	0.96	-0.98	0.55	-0.26	-0.53	0.33	-0.66	-0.7	-0.94	0.37	0.32	-0.24	1.0	0.73	0.02	-0.94	-0.73	-0.61
Current Deferred Revenue	0.73	-0.73	0.83	0.65	0.65	0.63	0.19	0.74		0.7	-0.78	0.52	0.16	-0.39	-0.06	-0.52	-0.48	-0.76	0.17	0.45	-0.14	0.75	0.49	0.19	-0.72	-0.25	-0.11
Net Debt	0.79	-0.86	0.94	0.81	0.96	0.64	0.45	0.96	0.7		-0.94	0.66	-0.14	-0.39	0.51	-0.62	-0.67	-0.9	0.4	0.34	-0.21	0.96	0.71	-0.11	-0.85	-0.76	-0.62
Retained Earnings	-0.73	0.95	-0.96	-0.87	-0.9	-0.67	-0.29	-0.98	-0.78	-0.94		-0.61	0.25	0.54	-0.32	0.66	0.63	0.95	-0.29	-0.39	0.14	-0.98	-0.66	-0.02	0.94	0.75	0.61
Accounts Payable	0.54	-0.47	0.52	0.84	0.58	0.28	0.25	0.55	0.52	0.66	-0.61		0.01	-0.18	0.49	-0.27	-0.05	-0.49	0.04	0.24	0.31	0.53	0.08	-0.11	-0.52	-0.6	-0.48
Net Receivables	0.26	0.35	-0.11	-0.25	-0.06	0.19	0.32	-0.26	0.16	-0.14	0.25	0.01		0.57	-0.09	0.33	-0.02	0.1	-0.1	0.15	-0.28	-0.26	-0.02	-0.05	0.24	0.57	0.62
Total Current Assets	-0.13	0.6	-0.52	-0.49	-0.22	-0.18	0.27	-0.53	-0.39	-0.39	0.54	-0.18	0.57		0.34	0.56	0.24	0.43	-0.12	-0.11	-0.19	-0.51	-0.2	0.26	0.51	0.41	0.21
Short Term Debt	0.31	-0.21	0.22	0.34	0.58	0.15	0.48	0.33	-0.06	0.51	-0.32	0.49	-0.09	0.34		-0.16	-0.26	-0.24	0.21	0.21	0.07	0.32	0.35	-0.14	-0.22	-0.65	-0.66
Short Term Investments	-0.33	0.78	-0.66	-0.4	-0.6	-0.54	0.2	-0.66	-0.52	-0.62	0.66	-0.27	0.33	0.56	-0.16		0.66	0.57	-0.33	-0.5	0.03	-0.66	-0.65	0.05	0.61	0.42	0.34
Treasury Stock	-0.63	0.65	-0.72	-0.28	-0.77	-0.81	-0.38	-0.7	-0.48	-0.67	0.63	-0.05	-0.02	0.24	-0.26	0.66		0.64	-0.43	-0.48	0.39	-0.7	-0.98	-0.08	0.66	0.27	0.23
Net Tangible Assets	-0.77	0.91	-0.94	-0.76	-0.88	-0.72	-0.35	-0.94	-0.76	-0.9	0.95	-0.49	0.1	0.43	-0.24	0.57	0.64		-0.2	-0.3	0.38	-0.94	-0.67	-0.05	0.95	0.62	0.48
Deferred Long Term Liab	0.3	-0.27	0.41	0.11	0.39	0.31	0.19	0.37	0.17	0.4	-0.29	0.04	-0.1	-0.12	0.21	-0.33	-0.43	-0.2		-0.17	-0.39	0.4	0.53	-0.19	-0.19	-0.24	-0.11
Long Term Investments	0.33	-0.39	0.33	0.28	0.42	0.44	0.11	0.32	0.45	0.34	-0.39	0.24	0.15	-0.11	0.21	-0.5	-0.48	-0.3	-0.17		0.3	0.32	0.43	0.01	-0.33	-0.14	-0.13
Short Long Term Debt	-0.32	0.16	-0.32	0.16	-0.29	-0.35	-0.27	-0.24	-0.14	-0.21	0.14	0.31	-0.28	-0.19	0.07	0.03	0.39	0.38	-0.39	0.3		-0.27	-0.41	-0.18	0.22	-0.15	-0.09
Long Term Debt Total	0.74	-0.94	0.98	0.79	0.92	0.68	0.33	1.0	0.75	0.96	-0.98	0.53	-0.26	-0.51	0.32	-0.66	-0.7	-0.94	0.4	0.32	-0.27		0.74	0.02	-0.92	-0.72	-0.6
Capital Surpluse	0.67	-0.68	0.74	0.31	0.81	0.81	0.42	0.73	0.49	0.71	-0.66	0.08	-0.02	-0.2	0.35	-0.65	-0.98	-0.67	0.53	0.43	-0.41	0.74		0.05	-0.67	-0.37	-0.28
Cash And Equivalents	0.1	-0.03	0.0	-0.02	0.03	0.18	0.02	0.02	0.19	-0.11	-0.02	-0.11	-0.05	0.26	-0.14	0.05	-0.08	-0.05	-0.19	0.01	-0.18	0.02	0.05		-0.19	0.26	-0.08
Net Invested Capital	-0.77	0.91	-0.9	-0.81	-0.85	-0.78	-0.31	-0.94	-0.72	-0.85	0.94	-0.52	0.24	0.51	-0.22	0.61	0.66	0.95	-0.19	-0.33	0.22	-0.92	-0.67	-0.19		0.63	0.52
Net Working Capital	-0.35	0.69	-0.6	-0.75	-0.68	-0.21	-0.22	-0.73	-0.25	-0.76	0.75	-0.6	0.57	0.41	-0.65	0.42	0.27	0.62	-0.24	-0.14	-0.15	-0.72	-0.37	0.26	0.63		0.87
Capital Stock	-0.17	0.57	-0.46	-0.63	-0.6	-0.1	-0.17	-0.61	-0.11	-0.62	0.61	-0.48	0.62	0.21	-0.66	0.34	0.23	0.48	-0.11	-0.13	-0.09	-0.6	-0.28	-0.08	0.52	0.87

Click cells to compare fundamentals

In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Competition

Predict Concord Medical

Ebitda Over Time

Concord Ebitda

Ebitda

(298.06 Million)

Concord Medical reported last year EBITDA of (313.75 Million)

According to the company disclosure, Concord Medical Services reported earnings before interest,tax, depreciation and amortization of (313.75 Million). This is 135.76% lower than that of the Health Care Providers & Services sector and significantly lower than that of the Health Care industry. The ebitda for all United States stocks is 108.05% higher than that of the company.

Concord EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Concord Medical's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Concord Medical could also be used in its relative valuation, which is a method of valuing Concord Medical by comparing valuation metrics of similar companies.

Concord Medical is currently under evaluation in ebitda category among its peers.

Concord Medical Current Valuation Drivers

We derive many important indicators used in calculating different scores of Concord Medical from analyzing Concord Medical's financial statements. These drivers represent accounts that assess Concord Medical's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Concord Medical's important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	806.3M	781.0M	555.0M	494.1M	356.5M	338.7M
Enterprise Value	2.6B	2.8B	3.1B	3.6B	3.6B	6.9B

Concord Medical ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Concord Medical's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Concord Medical's managers, analysts, and investors.

Environmental

Governance

Social

Concord Medical Institutional Holders

Institutional Holdings refers to the ownership stake in Concord Medical that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Concord Medical's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Concord Medical's value.

		Shares
Renaissance Technologies Corp	2024-03-31	40.7 K
Rhumbline Advisers	2024-03-31	5.5 K
Blackrock Inc	2024-03-31	0.0
Bank Of America Corp	2024-06-30	0.0
Ubs Group Ag	2024-03-31	0.0

Concord Fundamentals

	Return On Equity	-0.32
	Return On Asset	-0.044
	Profit Margin	(0.80) %
	Operating Margin	(0.90) %
	Current Valuation	489.18 M
	Shares Outstanding	2.82 M
	Shares Owned By Insiders	17.99 %
	Shares Owned By Institutions	0.29 %
	Number Of Shares Shorted	12.95 K
	Price To Earning	(3.90) X
	Price To Book	3.00 X
	Price To Sales	0.07 X
	Revenue	537.4 M
	Gross Profit	(152.41 M)
	EBITDA	(313.75 M)
	Net Income	(531.02 M)
	Cash And Equivalents	157.39 M
	Cash Per Share	1.72 X
	Total Debt	3.3 B
	Debt To Equity	1.25 %
	Current Ratio	0.71 X
	Book Value Per Share	(489.59) X
	Cash Flow From Operations	(276.47 M)
	Short Ratio	1.36 X
	Earnings Per Share	(12.18) X
	Target Price	1.2
	Number Of Employees	727
	Beta	-0.25
	Market Capitalization	34.73 M
	Total Asset	6.05 B
	Retained Earnings	(4.06 B)
	Working Capital	(1.33 B)
	Current Asset	1.51 B
	Current Liabilities	1.51 B
	Net Asset	6.05 B

About Concord Medical Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Concord Medical Services's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Concord Medical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Concord Medical Services based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Concord Medical Services is a strong investment it is important to analyze Concord Medical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Concord Medical's future performance. For an informed investment choice regarding Concord Stock, refer to the following important reports:

How To Invest In Concord

Details

Is Concord Stock a good investment?

Details

What is Concord Medical's Net Worth?

Details

Largest Health Care Providers & Services Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Concord Medical Piotroski F Score and Concord Medical Altman Z Score analysis.

You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Concord Medical. If investors know Concord will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Concord Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(12.18)

Revenue Per Share

107.978

Quarterly Revenue Growth

(0.23)

Return On Assets

(0.04)

Return On Equity

(0.32)

The market value of Concord Medical Services is measured differently than its book value, which is the value of Concord that is recorded on the company's balance sheet. Investors also form their own opinion of Concord Medical's value that differs from its market value or its book value, called intrinsic value, which is Concord Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Concord Medical's market value can be influenced by many factors that don't directly affect Concord Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Concord Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Concord Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Concord Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Concord Medical Services Stock EBITDA

Concord Medical Services Company EBITDA Analysis

EBITDA

Revenue

-

Basic Expenses

Current Concord Medical EBITDA

Concord EBITDA Driver Correlations

Concord Ebitda

Ebitda

(298.06 Million)

Concord EBITDA Peer Comparison

Concord Medical Current Valuation Drivers

Concord Medical ESG Sustainability

Concord Medical Institutional Holders

Concord Fundamentals

About Concord Medical Fundamental Analysis

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY